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Heat shock proteins (HSPs) and other members of the much broader stress protein family
have been shown to play important roles in coordinating multiple phases of immunolog-
ical reactions; from facilitating immunological recognition, to promoting and regulating
immunological responses and ﬁnally augmenting the resolution of inﬂammation and return
to immunological homeostasis. In this review, we consider the challenges facing the stress
protein ﬁeld as we enter 2012; in particular we consider the role that HSPs and stress
proteins may play in the initiation and termination of immunological responses. Special
attention is afforded to the resolution-associated molecular pattern, binding immunoglob-
ulin protein (BiP, also known as glucose regulated protein-78). We review the evidence
that resolution-promoting proteins such as BiP may herald a new generation of biolog-
ics for inﬂammatory disease and reﬂect on the challenges of achieving clinical remission
in rheumatoid arthritis with novel therapeutics and correlating clinical remission with
immunological parameters of resolution of inﬂammation.
Keywords: binding immunoglobulin protein, resolution-associatedmolecular patterns, inflammation, resolution of
inflammation, immunotherapy, rheumatoid arthritis, immune networks
INTRODUCTION
Heat shock proteins (HSP) and stress proteins are a collection of
highly evolutionarily conserved proteins, grouped by molecular
weight, with intracellular functions involving protein chaperon-
ing and folding and protection of the cell during physiologically
stressful conditions, including heat-shock, hypoxia, hypoglycemia,
and intracellular electrolyte abnormalities. The term “stress pro-
tein” provides an umbrella for all those proteins upregulated in
response to physiological stress, while HSP refers to the sub-family
of proteins that have speciﬁc promoters allowing them to respond
to heat shock. Stress proteins may be intracellular, cell surface
expressed, and/or extracellular proteins and, therefore, have access
to multiple subcellular and extracellular compartments. Conse-
quently, there has been much discussion around potential roles
that stress proteins may play in innate and adaptive immune
responses.
Immunological responses may be grouped into four overlap-
ping and interdependent phases: recognition, response, regulation,
and resolution. Much data suggest that stress proteins play impor-
tant roles in all of the phases of the immunological response.
In this review, we brieﬂy discuss how stress proteins can inﬂu-
ence the resolution of inﬂammation, in particular, with respect
to binding immunoglobulin protein (BiP, also known as glu-
cose regulated protein-78). We also explore the concept of third
generation biologic therapies for immunological diseases such as
rheumatoid arthritis (RA). The third generation of biologics for
immune-mediated diseases will be therapeutic agents that sig-
niﬁcantly modulate the dysregulated immune system, restoring
immune homeostasis for prolonged periods without further bio-
logic administration.Webelieve that BiP andothermembers of the
recently deﬁned resolution associated molecular pattern (RAMP)
family (Shields et al., 2011) may herald a new generation of such
novel biologics.
ELEPHANTS IN THE LABORATORY; A 2011 VIEW OF THE
STRESS PROTEIN FIELD
Extensive research has now shown that stress proteins are involved
in multiple stages of the immune response (Figure 1): stress
proteins participate in the recognition of immunological danger,
facilitate peptide carriage between cells and subsequent cross pre-
sentation of antigen, can modulate the immunological proﬁle of
myeloid lineage cells in both a pro- and anti-inﬂammatory direc-
tion and promote the regulation and resolution of inﬂammation.
However, research in the stress proteinﬁeldhas beendoggedby two
controversies for many years. Firstly, there remains suspicion that
stress protein family members possess no intrinsic immunological
activity and all observed activity is the consequence of bacterial
contaminants, particularly endotoxin, within the protein prepara-
tion (Wallin et al., 2002; Gao and Tsan, 2003a,b;Ye and Gan, 2007).
Secondly, compounding this problem, is the ever-increasing vari-
ety of cell surface receptors identiﬁed for HSP. Using HSP70 as
an example, the broad array of putative receptors include, TLR2,
TLR4, CD14, CD40, CD91, CCR5, LOX-1, SREC-1 (Calderwood
et al., 2007). However, there remain inconsistencies when trying to
replicate HSP binding to null cells transfected with some of these
speciﬁc molecules, such as CD14, TLR2, and TLR4, thus throwing
doubt on whether they are true receptors (Theriault et al., 2005).
The major challenge facing the stress protein ﬁeld is consoli-
dating and reﬁning the results of the extensive body of research
conducted to date into a more comprehensive theory of how
stress protein networks facilitate the initiation, progression, and
resolution of an immunological event. To achieve this, careful
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FIGURE 1 | How stress protein networks influences
immunological reactions. Immunological events can be broken
down into a series of interdependent phases: immunological
recognition, an immunological response following by regulation of
that response and resolution of inﬂammation leading to a return to
homeostasis. The stress protein network inﬂuences each phase of
the immunological event and ultimately, resolution-associated
molecular patterns may help facilitate the return to immunological
homeostasis. The different phases at which existing and future
therapeutics act are also illustrated.
distinctions should be made between the immunological activity
of mycobacterialHSP andmammalianHSP and,more pertinently,
between the immunological effects derived from whole extracel-
lular stress protein molecules and those effects caused by peptides
derived from stress protein molecules coordinating the generation
or expansion of self-reactive HSP T cells.
Moreover, stress protein researchers must address the elephants
in their experimental data. It is increasingly clear that stress pro-
teins bind bacterial products; however, the potential immunolog-
ical implications of stress protein–bacterial product interactions
have been over-shadowed by heated debate as to the immuno-
logical activity of ultra-pure stress protein preparations and their
role as damage-associated molecular patterns (DAMP; Gao and
Tsan, 2003a,b; Osterloh et al., 2004; Henderson et al., 2010). More
recently, further discussion has arisen surrounding subtle differ-
ences between danger-associated and DAMP (van Eden et al.,
2011), with van Eden et al. convincingly arguing that HSP should
be excluded from the DAMP family given the paucity of evidence
that they alone can activate an immunological response. Yet, the
very fact that HSP are upregulated in response to cellular stress
and can associate with pathogen associated molecular patterns
(PAMP) is of great immunological signiﬁcance in it’s own right,
particularlywith respect to thedanger hypothesis, for the following
reasons:
(1) Cellular stress is synonymous with potential threats to tissue
viability and is therefore synonymous with immunological
danger, in accordance with the danger hypothesis (Matzinger,
2002). Cellular stress can arise from infectious and non-
infectious sources (Macario and Conway de Macario, 2005;
Rath and Haller, 2011) and results in the upregulation and
redistribution of stress proteins, including members of the
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HSP family, to the cell surface and beyond, into the extra-
cellular ﬂuid (Multhoff and Hightower, 1996; Delpino and
Castelli, 2002; Mambula and Calderwood, 2006; Corrao et al.,
2010; Merendino et al., 2010; Sreekumar et al., 2010).
(2) Cell surface HSP and other stress proteins (e.g., gp96) signal
immunological danger by inducing and/or enhancing inﬂam-
matory cytokine production, dendritic cell (DC) maturation,
and NK cell activity (Chen et al., 2002; Liu et al., 2003; Oster-
loh et al., 2004). While this does not qualify the molecules as
DAMPs, as laid out in the criteria deﬁned by Kono and Rock
(2008), it emphasizes their importance in signaling immuno-
logical danger. Furthermore, while on the cell surface, it has
been hypothesized that stress proteins associate with PAMPs
and thus serve as a primitive antigen presentation system (Li
et al., 2002).
(3) There is considerable evidence to suggest that extracellular
HSP60, HSP70, HSP90, and gp96 bind to LPS and potenti-
ate its immunostimulatory effects (Triantaﬁlou et al., 2001;
Warger et al., 2006; Osterloh et al., 2007). High-mobility
group box protein-1 has shown similar properties (Pisetsky
et al., 2008). This suggests that stress proteins may facili-
tate the recognition of a pathogenic infection, particularly if
that infection has caused direct cellular insult. This may be
of signiﬁcance in maintaining immunological homeostasis at
epithelial surfaces.
(4) Beyond the cell, stress protein family members appear to bind
multiple extracellular protein and receptor targets (Calder-
wood et al., 2007). The immunological signiﬁcance of these
protein–protein interactions remain unclear. However, HSP
do appear to be “sticky” proteins. Given their interaction with
PAMPs, this promiscuity may facilitate the containment of
shed bacterial products, preventing their dissemination, while
providing a localized cache of PAMPs permitting a more
anatomically targeted immunological response.
In summary, the speciﬁc properties of an extracellular stress pro-
tein are likely to depend both on the protein itself, the surrounding
extracellular environment and the nature of the tissue from which
the stress protein was released. Furthermore, the possibility that
the extracellular environment modulates the activity of stress pro-
teins during the course of an immunological response requires fur-
ther attention; one could envisage a paradigm where extracellular
stress proteins evolve from poachers, inciting inﬂammation, and
tissue destruction, into gamekeepers, promoting regulation, and
resolution during the course of an immunological event. Indeed
a post-translational modiﬁcation of high-mobility G protein-1
(HMGB1) caused by oxidation attenuates pro-inﬂammatory func-
tions and makes the protein anti-inﬂammatory (Urbonaviciute
et al., 2009). However, since stress proteins exhibit such radically
different extracellular functions it should not be surprising that
they show different afﬁnities for a variety of receptors and may
even bind different receptors depending on cell type. Such activity
would enhance their ﬂexibility and diversity of function (Calder-
wood et al., 2007). Hence, a greater understanding of how the
stress protein network interacts with wider immunological net-
works would be extremely beneﬁcial, however, a systems biology
approach will likely be necessary to extend our knowledge further.
THE THIRD GENERATION OF BIOLOGICS: PROMOTING
RESOLUTION
At present all therapies for immune-mediated diseases – autoim-
mune or allotransplant – require either continuous administration
of immunosuppressive drugs or intermittent dosing at frequent
intervals. For example, despite the effectiveness of anti-TNF-α
therapy at suppressing inﬂammation in RA, cessation of ther-
apy is associated with clinical relapse and radiological progression
(Quinn et al., 2005) and although there is some in vitro evi-
dence that anti-TNF-α therapy may modulate adaptive immune
responses, particularly with respect to regulatory T cells (Ehren-
stein et al., 2004), there is little evidence that long-term therapy
alters the underlying immunological mechanisms that contribute
to the chronic autoimmune state. Indeed, even after achieving low
disease activity following long-term inﬂiximab treatment, 45% of
patients displayed further radiological disease progression within
just a year of cessation of therapy (Tanaka et al., 2010).
Nevertheless, the transplantation ﬁeld has offered hope that
physicians can induce a state of tolerance to alloantigen in the
absenceof long-term immunosuppression.Thebest-characterized
example of this phenomenon is liver transplantation: 20% of liver
transplant recipients are capable of achieving a state of clinical
operational tolerance (deﬁned as a well functioning graft, without
histological signs of rejection following the complete cessation of
immunosuppression for over 1 year; Orlando et al., 2009). Tol-
erance is rarer with other solid-organ transplants, but has been
reported in renal transplantation (Orlando et al., 2010); immu-
nologists are beginning to describe biomarkers and molecular
signatures that characterize and can be used to monitor clinical
operational tolerance which include reduced co-stimulatory mol-
ecule expression, immune quiescence, apoptosis, and memory T
cell responses are important in the maintenance of operational
tolerance (Brouard et al., 2007; Hernandez-Fuentes and Lechler,
2010).
With respect to RA, the clinical goal is not a tolerogenic state
per se, but the induction of drug-free remission. TheACR–EULAR
agreed deﬁnition of disease remission in RA is a simpliﬁed dis-
ease activity index (SDAI) of ≤13.3 at any one time, or a total
joint count of ≤1, and a swollen joint count ≤1, and a CRP
≤1mg/dl and a patient global assessment score of ≤1 (Bykerk,
2011). Remission of RA, may indeed involve the re-establishment
of immunological tolerance to cognate autoantigens. However,
extensive cell–cell interactions between immune and stromal cells
within the synovial architecture add a layer a complexity beyond
the extracelluar cytokine and stress protein networks that drive
the pathogenesis and maintain chronic inﬂammation within the
rheumatoid joint (McInnes and Schett, 2011).
Currently, rheumatologists do not possess any immunological
biomarkers to predict which patients will achieve or maintain a
state of disease-free remission or indeed the mechanisms by which
clinical remission is achieved (Isaacs, 2010). Thus, the attain-
ment of drug-free remission in RA is the premier challenge facing
rheumatologists and immunologist in the twenty-ﬁrst century.
Early, aggressive intervention in the disease process is now
the gold-standard for achieving maximum clinical response and
potential remission in the RA patient (Quinn et al., 2005). B-cell
depletion therapy has also offered a glimpse that more permanent
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changes to the immunological phenotype are possible. For exam-
ple, rituximab, a B-cell depleting anti-CD20 monoclonal anti-
body, induces enduring clinical responses that do not correlate
with peripheral blood levels of CD20+ B cells after treatment
(Breedveld et al., 2007). Multiple potential therapies and possi-
ble mechanisms for the re-establishment of immune tolerance
and subsequent resolution of chronic inﬂammation have been
discussed at length elsewhere (Albani et al., 2011). Needless to
say that, like the conditions necessary for operational tolerance of
renal grafts, tolerance in the rheumatoid patient involves modi-
ﬁcation of DC function such that T regulatory cells, of various
phenotypes and mode of action are generated.
Since stress proteins have pleiotropic functions, and have been
called “moonlighting” proteins (Huberts and van der Klei, 2010),
it may be that the immune down regulating properties of some
of them are due to an effect on DCs. Hence when used for the
treatment of human disease they may be able to produce pro-
longed drug-free disease remissions or even tolerance. What is
the evidence for this dramatic claim? Examination of the multiple
extracellular functions of BiP may provide an answer.
BiP – A BRIEF HISTORY
Binding immunoglobulin protein is a member of the HSP70 fam-
ily and an ubiquitously expressed, endogenous protein. BiP is
constitutively expressed in the endoplasmic reticulum (ER), and
essential for the correct folding of many nascent peptides (Geth-
ing, 1999). BiP is also the master regulator of the unfolded protein
response (UPR), a transcriptional program designed to relieve ER
stress by promoting the correct folding of ER luminal proteins
(Hendershot, 2004). BiP, therefore, is regulated at two levels, con-
stitutive and stress induced. Stress induced upregulation occurs
in environments of high cellular activity in inadequately vascu-
larized tissue, for example, during inﬂammation or neoplasia,
pathologies characterized by relative hypoglycemia and hypoxia
(Lee, 2007). Principally, during perturbation of the ER, BiP pro-
tects the cell from the accumulation of misfolded and denatured
proteins and, thus, prevents apoptosis. Testament to the funda-
mental importance of BiP is the fact that BiP knock-out mice
and mice where BiP is constitutively targeted to the incorrect sub-
cellular compartment are not viable (Luo et al., 2006; Mimura
et al., 2007). Many previous reviews have covered the intracellu-
lar chaperone function and protective role of BiP, during health
and disease, so these aspects of BiP biology will not be reviewed
here.
In contrast, our work for the last decade has focused exclu-
sively on the extracellular properties of cell-free human BiP and
its immunoregulatory role in inﬂammation. Like many other
stress proteins, BiP is now known to be cell surface expressed
and detectable at relatively high concentrations in serum, synovial
ﬂuid and oviductal ﬂuid (Delpino and Castelli, 2002; Corrigall
et al., 2004; Marin-Briggiler et al., 2010). As such, BiP has several
physiological properties. Although BiP is a member of the HSP70
family we have previously hypothesized that, unlike HSP70 itself,
BiP acts as a RAMP (Shields et al., 2011). RAMPs are protein
molecules released alongside DAMPs from stressed or necrotic
cells,which provide negative inputs into immunological networks,
antagonizing pro-inﬂammatory mediators, and helping restore
the immune system to homeostasis. Unlike the “DAMPing” or
regulatory effect that HSPs exert on the immune system which
appear to act via HSP derived peptides expanding sets of HSP-
speciﬁc regulatory T cells (van Eden et al., 2005; Quintana and
Cohen, 2011), the RAMP family members act predominantly on
the myeloid lineage, setting the scene for the resolution of inﬂam-
mation. Furthermore, what makes these molecules unique, is that
unlike the increasing number of resolution inducing molecules
being described (e.g., lipoxins and resolvins), the protein mem-
bers of the RAMP family are constitutively expressed and thus
able to affect the course of inﬂammation from the outset (Shields
et al., 2011).
BiP: DRIVING RESOLUTION OF INFLAMMATION
What sets BiP apart from other potential biologic therapeutics
appears to be its mode of action. Our research provides evidence
that BiP offers long-lasting prophylactic, and therapeutic protec-
tion fromdisease in themurinemodel of collagen induced arthritis
(CIA;Corrigall et al., 2001;Brownlie et al., 2006).Adoptive transfer
studies conﬁrm that the end-point of the mode of action involves
immunological changes to cell function and suggests that regula-
tory T cells are induced rapidly by BiP either in naïve animals,
following intravenous injection of BiP, or in vitro, when their
splenocytes and lymph nodes are cultured in the presence of BiP
(Corrigall et al., 2001; Brownlie et al., 2006). Importantly, the mes-
sage from these studies is that BiP-treated cells, when adoptively
transferred into arthritic mice are therapeutic and give long-term
relief in the absence of repeated administration.
Another indicator that BiP is a potentially successful therapeu-
tic in RA arises from our experimental pre-clinical investigation
into a xenogeneic model where small pieces of inﬂamed synovium
from RA patients were transplanted subcutaneously into severe
combined immunodeﬁcient (SCID) mice (Yoshida et al., 2011).
Following successful vascular anastomosis of the graft, a single
intravenous dose of BiP signiﬁcantly reduced histological features
of inﬂammation in the synovial explants. In addition, the his-
tological expression of pro-inﬂammatory cytokines (TNF-α and
IL-6) and the co-stimulatory molecules HLA-DR and CD86 was
signiﬁcantly down regulated in the grafts from the BiP-treated ani-
mals (Yoshida et al., 2011). The down-regulation of co-stimulatory
molecules would signiﬁcantly reduce the efﬁciency of antigen pre-
sentation. This SCID/RA synovial membrane chimera has been
used to validate other biologic therapies, anti-TNF-α neutralizing
antibody inhibitor and anti-soluble IL-6 receptor, that are now in
the clinic.
Binding immunoglobulin protein treatment induces key
changes in T cell and monocyte development. Firstly, T cell devel-
opment is skewed to a Th2 proﬁle with the production of IL-4,
IL-5, and IL-10 (Bodman-Smith et al., 2003). Human BiP-speciﬁc
T cell clones derived fromhealthy PBMCare predominantlyCD8+
and produce little or no interferon γ while splenocyte and lymph
node cell suspensions from BiP-treated CIA mice also show a Th2
proﬁle of cytokine release, IL-4, IL-5, and IL-10, on re-stimulation
with BiP in vitro (Brownlie et al., 2006). Serum samples from these
mice suggest that BiP suppresses the production of the pathogenic
anti-collagen type II antibodies, which drive CIA, while stimulat-
ing the production of non-pathogenic IgG1 isotype antibodies
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indicative of a Th2 environment (Brownlie et al., 2006). Sec-
ondly, BiP is capable of binding to a receptor expressed by >95%
human peripheral blood monocytes, up to 50% B cells and 10% T
cells (Corrigall et al., 2003). Currently, the identity of this recep-
tor(s) remains elusive. The immediate result of BiP stimulation,
in human peripheral blood mononuclear cells, is the attenuation
of TNF-α production after 7 h and increased IL-10 production
to a plateau lasting over 96 h (Corrigall et al., 2004). On being
stimulated by BiP, monocytes show phenotypic changes similar
to deactivated macrophages. Macrophage deactivation is achieved
via the stimulation of macrophages with IL-10, TGF-β, steroids, or
interactions betweenCD200 andCD200R andCD47 andCD172a;
the consequences of deactivation include increased production of
IL-10, TGF-β, PGE-2, and reduced expression of MHC-II mole-
cules (Gordon andTaylor, 2005). The various differentiation path-
ways and activation states of the monocyte–macrophage lineage
remain under intense investigation, however, BiP induced changes
are temporally different from those induced exclusively by IL-10.
The major effect is the complete inhibition of TNF-α production
with increased production of IL-10, soluble TNF receptors, and
IL-1 receptor antagonist (Corrigall et al., 2004). Ultimately, the
consequence of BiP stimulation is non-phlogistic activation of the
monocyte–macrophage. Monocytes cultured in the presence of
IL-4 and GM-CSF and BiP fail to differentiate into mature DC
(Corrigall et al., 2009). Remarkably these BiP-treated cells were
highly positive for indoleamine 2,3-dioxygenase (IDO), a charac-
teristic of tolerogenic DC. When these DCs were co-cultured with
autologous T cells they induced regulatory CTLA-4+ T cells. This
process was attributable to IDO up regulation because CTLA-4 up
regulation was reversible in the presence of 1 methyl tryptophan,
the IDO inhibitor. On separation from the DC the CTLA-4+ T
cells showed regulatory T cell function capable of suppressing T
cell stimulation by anti-CD3. Although BiP was essential for the
induction of the DCs, no additional BiP was required in the sec-
ondary cultures in which regulatory T cell function was assessed
(Corrigall et al., 2009). The mechanism underlying the induction
of regulatoryT cells byBiP is under investigationbyour laboratory.
There are three possible scenarios: ﬁrstly, that there is direct action
on the T cell via a receptor mediated process, but this is unlikely
given the relative lack of extracellular BiP protein in the culture
system during DC–T cell col-culture; secondly, that BiP drives the
induction of DC of a tolerogenic phenotype, including increasing
IDO expression, which we have shown directly leads to upregu-
lated CTLA-4+ regulatory T cells, either in the presence or absence
of peptide presentation. Finally BiP-speciﬁc peptide presentation
may expand existing regulatory T cells in a peptide dependent
process. Cross-reactivity with peptides from other HSP70 family
members is a possibility in this case as 68% amino acid homology
exists between HSP70 and BiP. If cross-reactivity between HSP70
and BiP occurs and is responsible for any of the T-cell dependent
regulatory effects of either protein, it lends further weight to the
hypothesis that an intricate network of extracellular stress pro-
teins exists which facilitates the maintenance of immunological
homeostasis (Panayi et al., 2004).
These studies are all in immunological models. In the TNF-α
transgenic mouse a spontaneous arthritis develops that resembles
RA in many of its features (Li and Schwarz, 2003) although the
joint inﬂammation and destruction is independent on immune
mechanisms. However, since BiP deactivates monocytes both at
the transcriptional and the translational level a prediction would
be that BiP would also have a therapeutic effect in this model.
Indeed a single intraperitoneal dose of BiP was able to signiﬁ-
cantly suppress joint inﬂammation and systemic bone damage for
several weeks (Corrigall et al., manuscript submitted).
The spontaneous arthritis observed in the transgenic mice is
almost certainly induced by TNF-α activation of transcription
factors including NF-κB, which is responsible for the induction
of many of the major inﬂammatory cytokines. Intracellularly, BiP
and NF-κB are counter regulated (Pahl and Baeuerle, 1995). A
recent review by Kitamura (2011) has reported that although early
UPR activity may drive NF-κB activation later UPR involvement
tends to attenuate NF-κB function. As an extracellular protein
we have shown that BiP acts to inhibit MAPK phosphorylation
(Corrigall et al., manuscript submitted) and downregulates pro-
tein levels of these signaling molecules. As a stress protein, BiP
is upregulated intracellularly in response to ER stress prior to its
release into the extracellular environment. Thus, both the intracel-
lular and extracellular actions of BiP may operate to diminish the
pro-inﬂammatory effects of NF-κB thus helping the resolution of
acute inﬂammation.
THE OTHER RESOLUTION-ASSOCIATED MOLECULAR
PATTERNS
Binding immunoglobulin protein is just one member of a fam-
ily of proteins we have recently deﬁned as the RAMPs. We have
extensively reviewed the properties of the RAMP family elsewhere
(Shields et al., 2011). Needless to say, we believe this family of pro-
teins, whose founder members include HSP10, HSP27, and α-B-
crystallin may have great potential as resolution-promoting thera-
peutics. Resolution-promoting regulatory signals are subtly differ-
ent from immunoregulatory immunological signals; resolution-
promoting signals are those that speciﬁcally promote the non-
phlogistic activation of macrophages, the phagocytosis of apop-
totic neutrophils, the prevention of inﬂux of inﬂammatory cells
and the restoration of parenchymal cells to the non-inﬂammatory
state (Serhan et al., 2007). The crux of resolution is, therefore,
centered around myeloid lineage cells and the parenchyma. This
is why we believe the RAMP family, which principally exert their
immunological effects via the myeloid lineage (thus affecting anti-
gen presentation, co-stimulatory molecule expression, myeloid
cell differentiation, and anti-inﬂammatory cytokine secretion (De
et al., 2000; Corrigall et al., 2004, 2009; Banerjee et al., 2011; Shields
et al., 2011)), have the potential to exert resolution-promoting
effects, rather than simply immunoregulatory effects.
Clinical trials of HSP10 have already yielded promising results
(Vanags et al., 2006; Williams et al., 2008) and pre-clinical models
have shown α-B-crystallin to be an extremely effective therapeutic
in a variety of different inﬂammatory disease models includ-
ing experimental autoimmune encephalomyelitis, ischemic optic
neuropathy and stroke (Ousman et al., 2007; Arac et al., 2011;
Pangratz-Fuehrer et al., 2011). Further investigations are necessary
to fully understand how the RAMP family exert their immunolog-
ical effects and under what circumstance they might be used in
clinical practice.
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CONCLUSION
To develop the third generation of biologics, a great deal of invest-
ment will need to be made in correlating the clinical parameters of
remission from chronic inﬂammatory disease and the immuno-
logical parameters of resolution from inﬂammation. Experience
from the rheumatological ﬁeld has shown us that aggressive
immunosuppressive and biological therapy can induce remis-
sion in early RA. However, the longer the disease progresses, the
more unlikely this strategy is to succeed because the mechanisms
controlling the regulation and resolution of inﬂammation fail
in chronic inﬂammation. Therapy in chronic inﬂammation can
reduce ongoing inﬂammation but does not resolve the underlying
immunological defect.
Evidence from our laboratory suggests that a single adminis-
tration of BiP in models of inﬂammatory arthritis is sufﬁcient to
regulate and resolve chronic inﬂammation. The planned Stage I/II
clinical trial of BiP in RA patients will teach us more regarding the
properties of BiP as a therapy in human disease. However, it may
be that resolution-promoting biologic therapies will have to be
administered in conjunction with other biologics, which can con-
trol ongoing inﬂammation and set-the-scene for immunological
resolution and restoration of homeostasis to occur.
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